PT  - JOURNAL ARTICLE
AU  - Oliveira, Tiago
AU  - Zhang, Mingfeng
AU  - Joo, Eun Ji
AU  - Abdel-Azim, Hisham
AU  - Chen, Chun-Wei
AU  - Yang, Lu
AU  - Chou, Chih-Hsing
AU  - Qin, Xi
AU  - Chen, Jianjun
AU  - Alagesan, Kathirvel
AU  - Almeida, Andreia
AU  - Jacob, Francis
AU  - Packer, Nicolle H.
AU  - Itzstein, Mark von
AU  - Heisterkamp, Nora
AU  - Kolarich, Daniel
TI  - Multi-<em>omics</em> of MLL-rearranged B-cell precursor acute lymphoblastic leukemia reveals broad glycoproteome remodelling
AID  - 10.1101/2021.06.25.21259296
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.25.21259296
4099  - http://medrxiv.org/content/early/2021/06/30/2021.06.25.21259296.short
4100  - http://medrxiv.org/content/early/2021/06/30/2021.06.25.21259296.full
AB  - B-cell precursor acute lymphoblastic leukemia (pre-B ALL) with mixed-lineage leukemia gene rearrangement (MLL-r) is a poor-prognosis subtype for which additional therapeutic targets are needed. To identify changes that could distinguish leukemic from normal precursor B-cells, we performed integrated multi-omics on primary patient samples. MLL-r cells feature an extensive remodelling of their glycoprotein glycocalyx, with increased Core 2-type O-glycans and complex N-glycans as well as significant changes in sialylation and fucosylation levels. Notably, a glycosaminoglycan remodelling from chondroitin sulfate to heparan sulfate was also observed. A survival screen to determine if glycan remodelling enzymes are redundant identified MGAT1 and NGLY1, components of the N-glycosylation/degradation pathway, as essential. OGT and OGA, unique enzymes that regulate intracellular O-GlcNAcylation, were also indispensable. Transcriptomics and proteomics further identified Fes and GALNT7-mediated glycosylation as possible therapeutic targets. Finally, next to well-known MLL-r pre-B ALL glycoprotein markers, our integrated multi-omics workflow identified previously unidentified diagnostic/therapeutic protein candidates.SIGNIFICANCE STATEMENT MLL-r is a poor-prognosis subtype of pre-B ALL, usually studied using genome- and transcriptome-centric approaches. MLL-r has one of the lowest survival rates in adults as well as children diagnosed with leukemia, as the majority of treatments available are least effective against this subtype. We performed the first multi-omics evaluation of primary MLL-r patient cells integrating glycome, proteome and transcriptome datasets. This enabled us to uncover that MLL-r cells undergo an extensive remodelling of the glycocalyx that differs to the one of normal pre-B cells in particular in cell surface glycoproteins, the O-glycome and proteoglycome. Our work opens new perspectives and evidence for potential future theranostic targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Leukemia Lymphoma Society (LLS) New Idea Award 2016/2017 (to N.H.), Civic Solutions Inc and Australian Research Council Future Fellowship FT160100344 (to D.K.), and the Griffith University Postgraduate Research Scholarship (GUPRS) (to T.O.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human specimen collection protocols were reviewed by Childrens Hospital Los Angeles Institution Review Board (IRB) and Committee on Clinical Investigations (CCI). Protocols for collection were approved and found to be in compliance with ethical practices by the Childrens Hospital Los Angeles Institution Review Board and Committee on Clinical Investigations. All specimens were de-identified/anonymized before acquisition for research. The specimens were collected as leftover specimens that were initially collected for clinical diagnostic purposes and were discarded as medical waste when no longer needed for clinical purposes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGlycomics data can be access on GlycoPOST using the following credentials: URL: https://glycopost.glycosmos.org/preview/192552055960853e1fc17f0 PIN code: 5775 Proteomics data can be accessed and reviewed on PRIDE using the following credentials: URL: https://www.ebi.ac.uk/pride Project Name: Altered glycoproteome of MLL-rearranged B-cell precursor acute lymphoblastic leukemia Project accession: PXD025354 Username: reviewer_pxd025354@ebi.ac.uk Password: FldtRJ8T https://glycopost.glycosmos.org/preview/192552055960853e1fc17f0 https://www.ebi.ac.uk/pride